InspireMD Q3 EPS $(0.15), Inline, Sales $1.56M Beat $1.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
InspireMD reported Q3 losses of $(0.15) per share, in line with analyst consensus. This is a 74.14% increase over losses from the same period last year. The company's quarterly sales of $1.56 million beat the analyst consensus estimate of $1.50 million by 3.73%, marking an 8.74% increase over sales from the same period last year.
November 06, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InspireMD's Q3 earnings were in line with estimates, and sales beat expectations. This could potentially have a positive impact on the company's stock.
InspireMD's Q3 earnings report shows that the company is performing in line with expectations, and even exceeding them in terms of sales. This could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100